http://finance.yahoo.com/news/sunshine-heart-present-upcoming-inv...

http://finance.yahoo.com/news/sunshine-heart-present-upcoming-investor-101500609.html


Sunshine Heart to Present at Upcoming Investor Conferences



EDEN PRAIRIE, Minn., Nov. 6, 2013 (GLOBE NEWSWIRE) -- Sunshine Heart, Inc. (SSH) today announced that the company is scheduled to present a corporate update at the following upcoming investor conferences for the balance of 2013:

2013 Credit Suisse Healthcare Conference

Presentation: Tuesday, November 12, 2013 at 9:30 AM MST at The Phoenician in Scottsdale, Arizona. Breakout session to immediately follow presentation at 10:00 AM MST

Presenting: Jeff Mathiesen, Chief Financial Officer

2013 Canaccord Genuity Medical Technology & Diagnostics Forum

Presentation: Thursday, November 14, 2013 at 3:30 PM EST at the Westin Grand Central in New York, New York

Presenting: Jeff Mathiesen, Chief Financial Officer

Barclays Select Series 2013: Growth Conference

Presentation: Tuesday, November 19, 2013 at 8:20 AM EST at 745 7th Ave in New York, New York (Club Room I)

Presenting: Kevin Bassett, Senior Vice President of Technology and Operations

Piper Jaffray 25th Annual Healthcare Conference

Presentation: Tuesday, December 3, 2013 at 1:30 PM EST at the New York Palace Hotel in New York, New York (Rutherford Room)

Presenting: Dave Rosa, Chief Executive Officer

Oppenheimer 24th Annual Healthcare Conference

Presentation: Wednesday, December 11, 2013 at 2:10 EST at the Crowne Plaza Hotel in New York, New York

Presenting: Jeff Mathiesen, Chief Financial Officer

About the C-Pulse(R) Heart Assist System

The C-Pulse Heart Assist System, or C-Pulse System, an investigational device in the United States, Canada and countries that do not recognize the CE mark approval, utilizes the scientific principles of intra-aortic balloon counterpulsation applied in an extra-aortic approach to assist the left ventricle by reducing the workload required to pump blood throughout the body, while increasing blood flow to the coronary arteries. Combined, these potential benefits may help sustain the patient's current condition or, in some cases, reverse the heart failure process, thereby potentially preventing the need for later-stage heart failure devices, such as left ventricular assist devices (LVADs), artificial hearts or transplants. It may also provide relief from the symptoms of Class III and ambulatory Class IV heart failure and improve quality of life and cardiac function. Based on the results from our feasibility trial, we also believe that some patients treated with our C-Pulse System will be able to stop using the device due to sustained improvement in their condition as a result of the therapy.